Alteogen completes clinical trial of ‘Herceptin’ biosimilar

Published: 2016-12-26 16:26:00
Updated: 2016-12-26 16:15:04

Alteogen announced the Phase 1 clinical trial of a biosimilar of Herceptin, a breast cancer therapy, which has been conducted in Canada since February, was successfully completed.

Alteogen has carried out the Phase 1 clinical trial after the company acquired its approval from ‘Health Canada’ las...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean




Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.